Emergent Biosolutions Share Price Today
(NASDAQ: EBS)

Name: Emergent Biosolutions Share Price Today (NASDAQ: EBS) - Emergent Biosolutions Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Emergent Biosolutions share price is $5.8 & ₹504.98 as on 6 Mar 2025, 2.30 'hrs' IST

$5.8

▲

-0.59

(-9.23%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Emergent Biosolutions share price in Dollar and Rupees. Guide to invest in Emergent Biosolutions stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Emergent Biosolutions, along with analyst recommendations, forecasts, and comprehensive financials.

Emergent Biosolutions share price movements

Today's Low: $5.78
Today's High: $6.49
$5.80
0.34%
Downside
Day's Volatility :10.94%
Upside
10.63%
52 Weeks Low: $1.82
52 Weeks High: $15.10
$5.80
68.62%
Downside
52 Weeks Volatility :87.95%
Upside
61.59%

Emergent Biosolutions (EBS) Returns

Period	Emergent Biosolutions Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-36.61%	3.7%	0.0%
6 Months	-23.98%	-2.8%	0.0%
1 Year	77.91%	2.5%	0.0%
3 Years	-85.91%	12.9%	-11.6%

Emergent Biosolutions (EBS) Key Statistics

in dollars & INR

Previous Close	$6.39
Open	$6.3
Today's High	$6.49
Today's Low	$5.78
Market Capitalization	$540.2M
Today's Volume	$1.8M
52 Week High	$15.1
52 Week Low	$1.8201
Revenue TTM	$1.1B
EBITDA	$-4.8M
Earnings Per Share (EPS)	$-11.22
Profit Margin	-18.55%
Quarterly Earnings Growth YOY	0.02%
Return On Equity TTM	-34.64%

How to invest in Emergent Biosolutions Stock (EBS) from India?

It is very easy for Indian residents to invest directly in Emergent Biosolutions from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Emergent Biosolutions stock in both Indian Rupees (INR) and US Dollars (USD). Search for Emergent Biosolutions or EBS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Emergent Biosolutions or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Emergent Biosolutions shares which would translate to 0.150 fractional shares of Emergent Biosolutions as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Emergent Biosolutions, in just a few clicks!

Returns in Emergent Biosolutions (EBS) for Indian investors in Rupees

The Emergent Biosolutions stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Emergent Biosolutions investment value today

Current value as on today

₹1,82,979

Returns

₹82,979

(+82.98%)

Returns from Emergent Biosolutions Stock

₹77,914 (+77.91%)

Dollar Returns

₹5,065 (+5.06%)

Indian investors sentiment towards Emergent Biosolutions (EBS)

145%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Emergent Biosolutions Stock from India on INDmoney has increased by 145% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Emergent Biosolutions

Vanguard Group Inc
5.91%
American Century Companies Inc
3.95%
State Street Corp
3.62%
BlackRock Inc
3.55%
Amvescap Plc.
2.84%
Millennium Management LLC
2.73%

Analyst Recommendation on Emergent Biosolutions

Sell

11%Buy

22%Hold

66%Sell

Based on 9 Wall street analysts offering stock ratings for Emergent Biosolutions(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Emergent Biosolutions Stock (EBS)

What analysts predicted

Upside of 106.9%

Target:

$12.00

Current:

$5.80

Insights on Emergent Biosolutions Stock (Ticker Symbol: EBS)

Price Movement
In the last 7 days, EBS stock has moved down by -17.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 254.7M → 293.8M (in $), with an average increase of 13.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -283.1M → 114.8M (in $), with an average increase of 346.6% per quarter
EBS vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 98.7% return, outperforming this stock by 20.8%
EBS vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 138.1% return, outperforming this stock by 224.2%
Price to Sales
ForEBS every $1 of sales, investors are willing to pay $0.3, whereas for Intra-cellular Therapies, Inc., the investors are paying $19.9 for every $1 of sales.

EBS Emergent Biosolutions Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$1.1B	↑ 41.36%
Net Income	$54.5M	↓ 13.08%
Net Profit Margin	4.93%	↓ 3.08%

	FY20	Y/Y Change
Revenue	$1.6B	↑ 40.63%
Net Income	$305.8M	↑ 461.1%
Net Profit Margin	19.66%	↑ 14.73%

	FY21	Y/Y Change
Revenue	$1.8B	↑ 15.26%
Net Income	$219.5M	↓ 28.22%
Net Profit Margin	12.24%	↓ 7.42%

	FY22	Y/Y Change
Revenue	$1.1B	↓ 37.47%
Net Income	$-223.8M	↓ 201.96%
Net Profit Margin	-19.97%	↓ 32.21%

	FY23	Y/Y Change
Revenue	$1.0B	↓ 6.39%
Net Income	$-760.5M	↑ 239.81%
Net Profit Margin	-72.48%	↓ 52.51%

	FY24	Y/Y Change
Revenue	$1.0B	↓ 0.54%
Net Income	$-190.6M	↓ 74.94%
Net Profit Margin	-18.26%	↑ 54.22%

	Q2 FY23	Q/Q Change
Revenue	$337.9M	↑ 104.66%
Net Income	$-261.3M	↑ 42.79%
Net Profit Margin	-77.33%	↑ 33.51%

	Q3 FY23	Q/Q Change
Revenue	$270.5M	↓ 19.95%
Net Income	$-265.9M	↑ 1.76%
Net Profit Margin	-98.3%	↓ 20.97%

	Q4 FY23	Q/Q Change
Revenue	$276.6M	↑ 2.26%
Net Income	$-49.5M	↓ 81.38%
Net Profit Margin	-17.9%	↑ 80.4%

	Q1 FY24	Q/Q Change
Revenue	$300.4M	↑ 8.6%
Net Income	$9.0M	↓ 118.18%
Net Profit Margin	3.0%	↑ 20.9%

	Q2 FY24	Q/Q Change
Revenue	$254.7M	↓ 15.21%
Net Income	$-283.1M	↓ 3245.56%
Net Profit Margin	-111.15%	↓ 114.15%

	Q3 FY24	Q/Q Change
Revenue	$293.8M	↑ 15.35%
Net Income	$114.8M	↓ 140.55%
Net Profit Margin	39.07%	↑ 150.22%

	FY19	Y/Y Change
Profit	$672.5M	↑ 46.16%

	FY20	Y/Y Change
Profit	$1.0B	↑ 53.37%

	FY21	Y/Y Change
Profit	$1.0B	↑ 0.37%

	FY22	Y/Y Change
Profit	$427.2M	↓ 58.73%

	FY23	Y/Y Change
Profit	$343.9M	↓ 19.5%

	FY24	Y/Y Change
Profit	$1.0B	↑ 203.46%

	Q2 FY23	Q/Q Change
Profit	$147.3M	↑ 1373.0%

	Q3 FY23	Q/Q Change
Profit	$93.7M	↓ 36.39%

	Q4 FY23	Q/Q Change
Profit	$74.8M	↓ 20.17%

	Q1 FY24	Q/Q Change
Profit	$139.4M	↑ 86.36%

	Q2 FY24	Q/Q Change
Profit	$-54.5M	↓ 139.1%

	Q3 FY24	Q/Q Change
Profit	$164.2M	↓ 401.28%

	FY19	Y/Y Change
Operating Cash Flow	$188.0M	↑ 349.76%
Investing Cash Flow	$-96.9M	↓ 89.2%
Financing Cash Flow	$-35.9M	↓ 104.55%

	FY20	Y/Y Change
Operating Cash Flow	$536.0M	↑ 185.11%
Investing Cash Flow	$-151.0M	↑ 55.83%
Financing Cash Flow	$69.5M	↓ 293.59%

	FY21	Y/Y Change
Operating Cash Flow	$321.1M	↓ 40.09%
Investing Cash Flow	$-225.0M	↑ 49.01%
Financing Cash Flow	$-141.0M	↓ 302.88%

	FY22	Y/Y Change
Operating Cash Flow	$-34.1M	↓ 110.62%
Investing Cash Flow	$-381.3M	↑ 69.47%
Financing Cash Flow	$481.2M	↓ 441.28%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-114.4M	↓ 37.83%
Investing Cash Flow	$257.7M	↓ 1806.62%
Financing Cash Flow	$-486.9M	↑ 4537.14%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$60.0M	↓ 152.45%
Investing Cash Flow	$-18.9M	↓ 107.33%
Financing Cash Flow	$-43.0M	↓ 91.17%

Emergent Biosolutions Technicals Summary

Sell

Neutral

Buy

Emergent Biosolutions is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Emergent Biosolutions (EBS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Emergent Biosolutions Inc	-45.74%	-23.98%	77.91%	-85.91%	-88.96%
Intra-cellular Therapies, Inc.	3.38%	81.15%	98.68%	146.46%	588.66%
Haleon Plc Spon Ads	10.71%	2.13%	26.53%	42.24%	42.24%
Zoetis Inc.	-3.04%	-10.5%	-9.01%	-11.21%	28.74%
Neurocrine Biosciences Inc.	-25.31%	-6.07%	-13.91%	29.45%	28.72%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Emergent Biosolutions Inc	69.58	NA	1.55	-1.15	-0.35	-0.04	NA	9.4
Intra-cellular Therapies, Inc.	NA	NA	0.0	0.13	-0.09	-0.07	NA	10.81
Haleon Plc Spon Ads	26.35	26.35	1.92	0.36	0.09	0.04	0.02	1.8
Zoetis Inc.	31.17	31.17	3.01	6.07	0.51	0.15	0.01	10.64
Neurocrine Biosciences Inc.	34.6	34.6	0.27	6.44	0.14	0.1	NA	26.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Emergent Biosolutions Inc	Sell	$540.2M	-88.96%	69.58	-18.55%
Intra-cellular Therapies, Inc.	Buy	$14.0B	588.66%	NA	-10.97%
Haleon Plc Spon Ads	Buy	$47.7B	42.24%	26.35	12.84%
Zoetis Inc.	Buy	$76.1B	28.74%	31.17	26.86%
Neurocrine Biosciences Inc.	Buy	$11.4B	28.72%	34.6	14.49%

About Emergent Biosolutions

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Organization	Emergent Biosolutions
Employees	1600
CEO	Mr. Joseph C. Papa Jr.
Industry	Health Technology

Management People of Emergent Biosolutions

Name	Title
Mr. Richard S. Lindahl M.B.A.	Executive VP, CFO & Treasurer
Ms. Coleen Glessner	Executive Vice President of Global Quality and Ethics & Compliance
Mr. Paul A. Williams	Senior Vice President of Products Business
Mr. Joseph C. Papa Jr.	CEO, President & Director
Ms. Jessica Perl	Senior VP, Corporate Secretary & General Counsel
Ms. Michelle Pepin	Senior VP & Chief Human Resource Officer
Ms. Stephanie Duatschek	Senior VP, Chief Strategy & Transformation Officer
Mr. William Hartzel	Senior Vice President of Manufacturing & Bioservices
Mr. Simon C. Lowry M.D.	Chief Medical Officer & Head of Research and Development

Important FAQs about investing in EBS Stock from India :

What is Emergent Biosolutions share price today?

Emergent Biosolutions share price today stands at $5.80, Open: $6.30 ; Previous Close: $6.39 ; High: $6.49 ; Low: $5.78 ; 52 Week High: $15.10 ; 52 Week Low: $1.82.

The stock opens at $6.30, after a previous close of $6.39. The stock reached a daily high of $6.49 and a low of $5.78, with a 52-week high of $15.10 and a 52-week low of $1.82.

Can Indians buy Emergent Biosolutions shares?

Yes, Indians can invest in the Emergent Biosolutions (EBS) from India.

With INDmoney, you can buy Emergent Biosolutions at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Emergent Biosolutions at zero transaction cost.

How can I buy Emergent Biosolutions shares from India?

It is very easy to buy Emergent Biosolutions from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Emergent Biosolutions (EBS) be purchased?

Yes, you can buy fractional shares of Emergent Biosolutions with INDmoney app.

What are the documents required to start investing in Emergent Biosolutions stocks?

To start investing in Emergent Biosolutions, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.